(Q46501916)

22 December 2017

title

A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer (English)

1 reference

22 December 2017

author name string

Eric Winquist

1

1 reference

22 December 2017

Malcolm J Moore

2

1 reference

22 December 2017

Kim N Chi

3

1 reference

22 December 2017

D Scott Ernst

4

1 reference

22 December 2017

Hal Hirte

5

1 reference

22 December 2017

Scott North

6

1 reference

22 December 2017

Jean Powers

7

1 reference

22 December 2017

Wendy Walsh

8

1 reference

22 December 2017

Therese Boucher

9

1 reference

22 December 2017

Robert Patton

10

1 reference

22 December 2017

Lesley Seymour

11

1 reference

22 December 2017

publication date

1 May 2005

1 reference

22 December 2017

published in

Urologic Oncology

1 reference

22 December 2017

volume

23

1 reference

22 December 2017

page(s)

143-149

1 reference

22 December 2017

issue

3

1 reference

22 December 2017

Targeting RAS signalling pathways in cancer therapy

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.12.012

Farnesyl transferase inhibitors as anticancer agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.12.012

Bladder cancer. I. Molecular and genetic basis of carcinogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.12.012

Agents targeting ras signaling pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.12.012

A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.12.012

A phase II trial of daily perillyl alcohol in patients with advanced ovarian cancer: Eastern Cooperative Oncology Group Study E2E96.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.12.012

The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.12.012

c-myc down-regulation induces apoptosis in human cancer cell lines exposed to RPR-115135 (C31H29NO4), a non-peptidomimetic farnesyltransferase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.12.012

The farnesyl transferase inhibitor RPR-130401 does not alter radiation susceptibility in human tumor cells with a K-Ras mutation in spite of large changes in ploidy and lamin B distribution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.12.012

Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.12.012

Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.12.012

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.12.012

Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.12.012

Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.12.012

Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.12.012

Molecular alterations in bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.12.012

Transcriptional activation of H-ras, K-ras and N-ras proto-oncogenes in human bladder tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.12.012

Activity of SCH 66336, a tricyclic farnesyltransferase inhibitor, against human tumor colony-forming units

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.12.012

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.12.012

Nonparametric Estimation from Incomplete Observations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.12.012

The farnesyl protein transferase inhibitor lonafarnib (SCH66336) is an inhibitor of multidrug resistance proteins 1 and 2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.12.012

10.1016/J.UROLONC.2004.12.012

7 January 2021

Identifiers

DOI

1 reference

22 December 2017

release_oiqos5kaufeelpvrmeawws5nyq

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/oiqos5kaufeelpvrmeawws5nyq

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

15907712

1 reference

22 December 2017